LimmaTech Biologics, a Schlieren, Switzerland-based developer of a multi-antigen vaccine platform, raised additional $3M in Series A funding.
The ruond, which brought the total amount to $40M, was led by Tenmile. The new funding followed the initial Series A closing co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
The company intends to use the funds to further advance its proprietary platform and to accelerate the preclinical and clinical development of its vaccine candidate pipeline.
Led by CEO Dr. Franz-Werner Haas, LimmaTech Biologics aims to fight the global antimicrobial resistance epidemic based on its vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to provide solutions against increasingly dangerous infections, with specific programs addressing Staphylococcus aureus, Shigella, and sexually transmitted diseases like gonorrhea.
Commenting on the news, Franz-Werner Haas said: “With the strong support from our investors, our focus for 2024 is to achieve key milestones with both our preclinical and our clinical vaccine candidates, starting with new clinical trials for our Staphylococcus aureus candidate in Phase 1 and Shigella vaccine candidate in Phase 2, as well as further developments of our proprietary technology platform.”
FinSMEs
01/02/2024